Plasmodium immunotherapy - CAS Lamvac Biotech
Alternative Names: Plasmodium cancer vaccine - CAS Lamvac Biotech; Plasmodium immunotherapy for cancerLatest Information Update: 18 Jul 2023
At a glance
- Originator Guangzhou Institutes of Biomedicine and Health
- Developer CAS Lamvac Biotech; State Key Laboratory of Respiratory Disease
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Breast cancer; Liver cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 07 Jul 2023 CAS Lamvac Biotech and The Third Affiliated Hospital of Southern Medical University plan a phase II/III trial for Liver cancer (Late-stage disease, Second-line therapy or greater) in China (Parenteral), in August 2023 , (NCT05924776)
- 24 Oct 2019 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in China (Parenteral) (NCT04165590)
- 01 Jan 2018 Phase-I/II clinical trials in Breast cancer (Late-stage disease) in China (Parenteral) (ChiCTR1800015253)